Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study.
Andrea ChiricozziS M FerrucciL Di NardoN GoriA BalatoM OrtoncelliMartina MaurelliMarco GalluzzoM Munera CamposT SeremetGiacomo CaldarolaC De SimoneE IppolitiTiago TorresS GkalpakiotisC ConradJ M CarrascosaL BianchiG ArgenzianoS RiberoG GirolomoniA V MarzanoK Perisnull nullPublished in: Expert opinion on biological therapy (2023)
This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.